Ganga Pharmaceuticals (539680) H2 19/20 earnings summary

Executive summary

• FY20 revenue declined to ₹307.88 lakh from ₹336.26 lakh; profit after tax edged up to ₹18.88 lakh from ₹18.71 lakh.

• Performance faced weakening macro conditions and late-year COVID-19 disruption; mitigation plans were initiated to limit effects on revenue and profitability.

Financial highlights

• Revenue from operations was ₹307.88 lakh vs ₹336.26 lakh in FY19; other income was ₹16.51 lakh vs ₹14.39 lakh.

• Profit before tax was ₹25.51 lakh vs ₹25.85 lakh; profit after tax was ₹18.88 lakh vs ₹18.71 lakh.

• Total expenses declined to ₹298.89 lakh from ₹324.80 lakh; sales and administrative expenses fell to ₹77.60 lakh from ₹95.69 lakh.

Outlook and guidance

• Long-term strategy centers on scaling authentic Ayurveda, customer-focused services, domestic market growth, expanded distribution, and new products for diabetes, inflammation and obesity.

• Plans include product development for unmet medical needs, clinical validation of selected formulations, and investment in distribution networks and patented products.